Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 8/20 | 1.00 |
| ▸ | KDR | P35968 | 8/20 | 1.00 |
| ▸ | AXL | P30530 | 4/20 | 1.00 |
| ▸ | FLT3 | P36888 | 2/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 1/20 | 1.00 |
| ▸ | KIT | P10721 | 1/20 | 1.00 |
| ▸ | NTRK2 | Q16620 | 1/20 | 1.00 |
| ▸ | MST1R | Q04912 | 12/20 | 0.76 |
| ▸ | MERTK | Q12866 | 2/20 | 0.76 |
| ▸ | PLK4 | O00444 | 1/20 | 0.76 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.76 |
| ▸ | ABL1 | P00519 | 1/20 | 0.76 |
| ▸ | LCK | P06239 | 1/20 | 0.76 |
| ▸ | FYN | P06241 | 1/20 | 0.76 |
| ▸ | LYN | P07948 | 1/20 | 0.76 |
| ▸ | HCK | P08631 | 1/20 | 0.76 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.76 |
| ▸ | BCR | P11274 | 1/20 | 0.76 |
| ▸ | SRC | P12931 | 1/20 | 0.76 |
| ▸ | ABL2 | P42684 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sitravatinib SCHEMBL29774217 | 1.00 | MET (1.00) | METKDRAXLFLT3NTRK1 | |
| Sitravatinib SCHEMBL172015 | 1.00 | MET (1.00) | METKDRAXLFLT3NTRK1 | |
| Sitravatinib SCHEMBL30276257 | 1.00 | MET (1.00) | METKDRAXLFLT3NTRK1 | |
| SCHEMBL23118344 | 0.96 | MET (0.92) | METKDRAXLFLT3NTRK1 | |
| SCHEMBL12557940 | 0.96 | MET (0.92) | METKDRAXLFLT3NTRK1 | |
| Sitravatinib SCHEMBL26109867 | 0.96 | MET (0.91) | METKDRAXLFLT3NTRK1 | |
| Sitravatinib SCHEMBL29927268 | 0.96 | MET (0.91) | METKDRAXLFLT3NTRK1 | |
| Sitravatinib SCHEMBL29910958 | 0.96 | MET (0.91) | METKDRAXLFLT3NTRK1 | |
| SCHEMBL2605829 | 0.95 | MET (0.91) | METKDRAXLFLT3NTRK1 | |
| SCHEMBL14817556 | 0.95 | MET (0.91) | METKDRAXLFLT3NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1021 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559800-B2 | KMT2A-MAML2 fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2026-02-24 | — | — | US | claimed |
| EP-4694930-A1 | COMBINATION THERAPIES INVOLVING GREM1 ANTAGONISTS FOR TREATMENT OF CANCER | Suzhou Transcenta Therapeutics Co., Ltd. (CN) | 2026-02-18 | — | — | EP | claimed |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2025-12-18 | — | — | US | claimed |
| EP-4653019-A1 | ANTI-HER2 ANTIBODY-DRUG CONJUGATE FOR TREATING BREAST CANCER | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2025-11-26 | — | — | EP | claimed |
| EP-3957329-B1 | COMPOSITION COMPRISING THE COMBINATION OF SOTAGLIFLOZIN AS THE SODIUM/GLUCOSE CO-TRANSPORTER 1 INHIBITOR (SGLT1) AND A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 INHIBITOR (VEGFR2) FOR USE IN TREATING CANCER | NEWISH TECH BEIJING CO LTD (CN) | 2025-11-19 | — | — | EP | claimed |
| EP-4640714-A2 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | PML Screening, LLC (US) | 2025-10-29 | — | — | EP | claimed |
| EP-4637821-A1 | HER3 RADIOIMMUNOTHERAPY FOR THE TREATMENT OF SOLID CANCERS | Actinium Pharmaceuticals, Inc. (US) | 2025-10-29 | — | — | EP | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| EP-3957631-B1 | QUINOLINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING EWING'S SARCOMA | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2025-09-10 | — | — | EP | claimed |
| EP-4604920-A1 | LYOPHILIZED FORMULATIONS OF CD73 COMPOUNDS | Arcus Biosciences, Inc. (US) | 2025-08-27 | — | — | EP | claimed |
| EP-3973963-A1 | QUINOLINE DERIVATIVES FOR TREATMENT OF HEAD AND NECK CANCER | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2022-03-30 | — | — | EP | claimed |
| US-11285154-B2 | Methods and compositions for treating cancer | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2022-03-29 | — | — | US | claimed |
| WO-2022060831-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. (US) | 2022-03-24 | — | — | WO | claimed |
| EP-3967310-A1 | QUINOLINE DERIVATIVE USED FOR SOFT TISSUE SARCOMA COMBINATION THERAPY | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-03-16 | — | — | EP | claimed |
| EP-3964217-A1 | USE OF COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT, DIMER OR TRIMER THEREOF IN PREPARATION OF DRUG FOR TREATING CANCER | Newish Technology (Beijing) Co., Ltd. (CN) | 2022-03-09 | — | — | EP | claimed |
| WO-2022043816-A2 | RATIONAL IDENTIFICATION OF FDA APPROVED DRUGS BY COMPUTATIONAL MODELLING AND INHIBITION OF RBD/ACE2 BINDING FOR TREATMENT OF COVID-19 | REAGENE INNOVATIONS PVT. LTD. (IN) | 2022-03-03 | — | — | WO | claimed |
| EP-3957310-A1 | COMPOSITION AND USE THEREOF IN PREPARATION OF MEDICATION FOR TREATING CANCER | Newish Technology (Beijing) Co., Ltd. (CN) | 2022-02-23 | — | — | EP | claimed |
| EP-3957631-A1 | QUINOLINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING EWING'S SARCOMA | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2022-02-23 | — | — | EP | claimed |
| EP-3957329-A1 | COMPOSITION FOR TREATING CANCER, APPLICATION THEREOF, AND DRUG | Newish Technology (Beijing) Co., Ltd. (CN) | 2022-02-23 | — | — | EP | claimed |
| EP-3942045-A1 | A DBAIT MOLECULE IN COMBINATION WITH KINASE INHIBITOR FOR THE TREATMENT OF CANCER | ONXEO (FR) | 2022-01-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559800-B2 | KMT2A-MAML2 fusion molecules and uses thereof | DNER, EGFR, NOTCH2 | MET 9/4885KDR 498/4885AXL 727/4885 |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | KIT, CTSL, PAICS | MET 124/4885KDR 328/4885AXL 497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.